

# FOUNDATION SEMINAR IN INFECTIOUS DISEASES

## Foundation Seminar in Infectious Diseases

### Preliminary program

Self-paced learning package: from Friday 6 May 2021

Topic and presenter	Learning objectives
Principles of infectious diseases	<ul style="list-style-type: none"> <li>Describe the Physician's approach to clinical assessment including clinical investigations commonly undertaken</li> <li>Discuss principles of good antimicrobial prescribing</li> <li>Discuss the clinical monitoring required for patients on antimicrobial treatment and the clinical approach to antimicrobial failure</li> </ul>
Principles of microbiology	<ul style="list-style-type: none"> <li>Discuss the role of the microbiology laboratory in the management of infectious diseases, antimicrobial prescribing and infection control</li> <li>Interpret a typical laboratory report</li> <li>Discuss important Gram-positive and Gram-negative organisms in hospital</li> </ul>
Principles of Antimicrobial Stewardship	<ul style="list-style-type: none"> <li>Discuss principles of antimicrobial stewardship (AMS)</li> <li>Identify IV to oral switch criteria</li> <li>List examples of AMS interventions that can be applied in daily practice</li> </ul>
Introduction to PK/PD	<ul style="list-style-type: none"> <li>Describe the major pharmacokinetic (PK) and pharmacodynamic (PD) parameters of commonly used antimicrobials</li> <li>Apply PK/PD principles in order to optimize antimicrobial dosing and minimize toxicity in an individual patient</li> </ul>
Therapeutic drug monitoring in practice	<ul style="list-style-type: none"> <li>Identify the practical issues surrounding TDM of antimicrobials, including the role for pharmacists</li> </ul>

# FOUNDATION SEMINAR IN INFECTIOUS DISEASES

<p>Management of respiratory infections</p>	<ul style="list-style-type: none"> <li>• Describe the signs, symptoms, pathophysiology and principles of management of community acquired pneumonia (CAP) and hospital acquired pneumonia (HAP)</li> <li>• Identify risk factors for HAP caused by multi-drug resistant gram-negative organisms</li> <li>• Compare tools available for the assessment of severity of CAP, e.g. PSI, SMART-COP, CORB</li> <li>• Describe the appropriate antimicrobial management for treatment and prophylaxis of influenza</li> </ul>
<p>Sepsis</p>	<ul style="list-style-type: none"> <li>• Explain the definitions of sepsis and recognize the key clinical signs of sepsis</li> <li>• Describe the key principles in the management of sepsis including empirical antimicrobial therapy and fluids and monitoring requirements</li> <li>• Identify common sources of sepsis and high risk populations</li> <li>• Recognise the benefits of implementing a hospital sepsis pathway</li> </ul>
<p>Management of urinary tract infections</p>	<ul style="list-style-type: none"> <li>• Describe the signs, symptoms, pathophysiology and principles of management of uncomplicated and complicated urinary tract infections (UTIs)</li> <li>• Describe empiric treatment including dose and duration of therapy based on local and national guidelines</li> <li>• Identify risk factors for UTIs caused by multi-drug resistant gram-negative organisms</li> <li>• Discuss the role of prophylaxis for prevention of UTIs</li> </ul>
<p>Skin and soft tissue infections</p>	<ul style="list-style-type: none"> <li>• Describe the underlying risk factors and pathophysiology and evidence-based empiric management of cellulitis</li> <li>• Describe the management of skin and soft tissue infections (SSTIs) in the following specialty populations: intravenous drug users, diabetic patients, wounds with water exposure</li> <li>• Discuss the management of recurrent staphylococcal infection, including decolonization</li> <li>• Describe the rationale and principles for the route of administration, timing and duration for surgical antimicrobial prophylaxis</li> </ul>
<p>Introduction to fungal infections</p>	<ul style="list-style-type: none"> <li>• Discuss the pathophysiology and clinical features of common fungal infections</li> <li>• Identify risk factors and clinical conditions that predispose patients to fungal infection</li> <li>• Describe the patient populations who are at risk of contracting invasive candidiasis</li> <li>• Discuss the pharmacology, clinical pharmacokinetics and major adverse effects of antifungal agents</li> </ul>

# FOUNDATION SEMINAR IN INFECTIOUS DISEASES

## Foundation Seminar in Infectious Diseases

Live virtual seminar: Saturday 18 June 2022

Time (AEST)	Session
0920-0930	Online login and registration available
0930-0940	Welcome and introductions
0940-1030	Review of online learning content and Q&A
1030-1130	Case session 1: Vancomycin and therapeutic drug monitoring
1130-1200	Break
1200-1315	Case session 2: Respiratory / sepsis infections
1315-1415	Case session 3: Fungal infections
1415-1445	Break
1445-1600	Case session 4: Urinary tract infections
1600-1630	Final Q&A, seminar summary and close
1630	Seminar close